321 related articles for article (PubMed ID: 21222550)
1. Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?
Imbimbo BP; Panza F; Frisardi V; Solfrizzi V; D'Onofrio G; Logroscino G; Seripa D; Pilotto A
Expert Opin Investig Drugs; 2011 Mar; 20(3):325-41. PubMed ID: 21222550
[TBL] [Abstract][Full Text] [Related]
2. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
[TBL] [Abstract][Full Text] [Related]
3. Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Curr Med Chem; 2011; 18(35):5430-47. PubMed ID: 22087836
[TBL] [Abstract][Full Text] [Related]
4. γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes.
Imbimbo BP; Giardina GA
Curr Top Med Chem; 2011; 11(12):1555-70. PubMed ID: 21510832
[TBL] [Abstract][Full Text] [Related]
5. Are γ-secretase inhibitors detrimental for Alzheimer's disease patients?
Ross JS; Imbimbo BP
J Alzheimers Dis; 2010; 22(2):401-4. PubMed ID: 21149978
[TBL] [Abstract][Full Text] [Related]
6. γ-Secretase as a target for Alzheimer's disease.
Wolfe MS
Adv Pharmacol; 2012; 64():127-53. PubMed ID: 22840746
[TBL] [Abstract][Full Text] [Related]
7. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
8. REVIEW: γ-Secretase inhibitors for the treatment of Alzheimer's disease: The current state.
Panza F; Frisardi V; Imbimbo BP; Capurso C; Logroscino G; Sancarlo D; Seripa D; Vendemiale G; Pilotto A; Solfrizzi V
CNS Neurosci Ther; 2010 Oct; 16(5):272-84. PubMed ID: 20560993
[TBL] [Abstract][Full Text] [Related]
9. Secretase inhibitors and modulators for Alzheimer's disease treatment.
Tomita T
Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
[TBL] [Abstract][Full Text] [Related]
10. Advances in gamma-secretase modulation.
Pissarnitski D
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):392-402. PubMed ID: 17659480
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of gamma-secretase inhibitors and modulators.
Imbimbo BP
Curr Top Med Chem; 2008; 8(1):54-61. PubMed ID: 18220933
[TBL] [Abstract][Full Text] [Related]
12. Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches.
Mikulca JA; Nguyen V; Gajdosik DA; Teklu SG; Giunta EA; Lessa EA; Tran CH; Terak EC; Raffa RB
J Clin Pharm Ther; 2014 Feb; 39(1):25-37. PubMed ID: 24313554
[TBL] [Abstract][Full Text] [Related]
13. gamma-Secretase as a target for drug intervention in Alzheimer's disease.
Harrison T; Churcher I; Beher D
Curr Opin Drug Discov Devel; 2004 Sep; 7(5):709-19. PubMed ID: 15503873
[TBL] [Abstract][Full Text] [Related]
14. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
15. The structure and function of Alzheimer's gamma secretase enzyme complex.
Krishnaswamy S; Verdile G; Groth D; Kanyenda L; Martins RN
Crit Rev Clin Lab Sci; 2009; 46(5-6):282-301. PubMed ID: 19958215
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
[TBL] [Abstract][Full Text] [Related]
17. Structural optimization of a CXCR2-directed antagonist that indirectly inhibits gamma-secretase and reduces Abeta.
Bakshi P; Jin C; Broutin P; Berhane B; Reed J; Mullan M
Bioorg Med Chem; 2009 Dec; 17(23):8102-12. PubMed ID: 19853461
[TBL] [Abstract][Full Text] [Related]
18. Gamma-secretase: a complex target for Alzheimer's disease.
Lundkvist J; Näslund J
Curr Opin Pharmacol; 2007 Feb; 7(1):112-8. PubMed ID: 17169612
[TBL] [Abstract][Full Text] [Related]
19. Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators.
Panza F; Solfrizzi V; Frisardi V; Capurso C; D'Introno A; Colacicco AM; Vendemiale G; Capurso A; Imbimbo BP
Drugs Aging; 2009; 26(7):537-55. PubMed ID: 19655822
[TBL] [Abstract][Full Text] [Related]
20. Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease.
Imbimbo BP; Peretto I
Curr Opin Investig Drugs; 2009 Jul; 10(7):721-30. PubMed ID: 19579178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
